This activity was originally presented at the 2024 HOPA Annual Conference in Tampa, Florida.
Program Description
While chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are distinct B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors have emerged as effective therapeutic options in both disease states. Guideline recommendations for the use of BTK inhibitors in CLL and MCL vary and require that oncology pharmacists are familiar with supporting data for each recommendation when selecting therapies for individual patients. Despite improved response and survival rates, BTK inhibitors are associated with treatment resistance and poor tolerability, resulting in high discontinuation rates. This program will explore treatment expectations with covalent BTK inhibitor therapy and examine how the development of novel noncovalent BTK inhibitors may overcome existing treatment challenges. The discussion will prepare pharmacists to appropriately recommend preferred regimens in CLL and MCL while minimizing serious and frequently encountered adverse effects, including cardiovascular toxicities, optimizing adherence, and improving access to BTK inhibitor therapies.
Target Audience: Oncology pharmacists
Type of Activity: Application
Release date: April 12, 2024
Expiration date: April 12, 2025
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze the current guidelines and recommendations for incorporating Bruton tyrosine kinase (BTK) inhibitors into chronic lymphocytic leukemia (CLL) and relapsed/refractory mantle cell lymphoma (R/R MCL) treatment strategies
- Investigate emerging data and ongoing research that may impact the evolving role of BTK inhibitors in CLL and R/R MCL treatment
- Construct a decision-making framework for selecting the most appropriate BTK inhibitor for individual patients based on unique clinical characteristics
- Identify strategies for the proactive management and mitigation of adverse effects of BTK inhibitors, including appropriate dose adjustments, symptom management, and patient counseling
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
